HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice
DIR@IMTECH: CSIR-Institute of Microbial Technology
View Archive InfoField | Value | |
Title |
HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice
|
|
Creator |
Tyagi, Rajeev K
Jacobse, Justin Li, Jing Allaman, Margret M. Otipoby, Kevin L. Sampson, Erik R. Wilson, K T Goettel, Jeremy A. |
|
Subject |
QR180 Immunology
|
|
Description |
Regulatory T (T-reg) cells are essential to maintain immune homeostasis in the intestine and T-reg cell dysfunction is associated with several inflammatory and autoimmune disorders including inflammatory bowel disease (IBD). Efforts using low-dose (LD) interleukin-2 (IL-2) to expand autologous T-reg cells show therapeutic efficacy for several inflammatory conditions. Whether LD IL-2 is an effective strategy for treating patients with IBD is unknown. Recently, we demonstrated that LD IL-2 was protective against experimental colitis in immune humanized mice in which human CD4(+) T cells were restricted to human leukocyte antigen (HLA). Whether HLA restriction is required for human T-reg cells to ameliorate colitis following LD IL-2 therapy has not been demonstrated. Here, we show that treatment with LD IL-2 reduced 2,4,6-trinitrobenzensulfonic acid (TNBS) colitis severity in NOD.Prkdc(scid)Il2rg(-/-) (NSG) mice reconstituted with human CD34(+) hematopoietic stem cells. These data demonstrate the utility of standard immune humanized NSG mice as a pre-clinical model system to evaluate therapeutics targeting human T-reg cells to treat IBD.
|
|
Publisher |
Frontiers
|
|
Date |
2021-02-24
|
|
Type |
Article
PeerReviewed |
|
Relation |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.630204/full
http://crdd.osdd.net/open/2660/ |
|
Identifier |
Tyagi, Rajeev K and Jacobse, Justin and Li, Jing and Allaman, Margret M. and Otipoby, Kevin L. and Sampson, Erik R. and Wilson, K T and Goettel, Jeremy A. (2021) HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice. Frontiers in immunology, 12. ISSN 1664-3224
|
|